More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
In a text message, Grisham confirmed to CNBC that she will still be working for the first lady even as she takes on her new roles.Politicsread more
Acting Customs and Border Protection Commissioner John Sanders is resigning amid the furor over the Trump administration's treatment of migrant children.Politicsread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Warren's election reform proposal includes standardized federal election rules, increased federal oversight of elections, and a constitutional amendment guaranteeing voting...Politicsread more
Apple's iOS 13 is coming this fall, but you can already try it on your iPhone with the new public beta. Here are some of the best hidden features.Technologyread more
Even if the debate stage will be more crowded than ever, recent history shows they can reveal the candidates' skills and character - even if the two stand at odds.Politicsread more
Micron beat analyst estimates on earnings and revenue for its fiscal third quarter of 2019.Technologyread more
Investors are piling into gold, sending the precious metal to a six-year high, and analysts think the commodity has established a base to go even higher.Marketsread more
Trump slams Iran on Twitter for issuing a "very ignorant and insulting statement" after the U.S. slapped fresh sanctions on Tehran.Politicsread more
(Adds details on approval, lymphoma)
June 10 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to Roche Holding AG's combo lymphoma treatment for previously treated patients, the company said on Monday.
The drug, Polivy, is used in combination with Rituxan and a chemotherapy agent to treat an aggressive form of the disease.
The combo is used to treat adults, who have received at least two prior therapies for relapsed or refractory form of non-Hodgkin's lymphoma (NHL).
Roche estimates that nearly 25,000 new cases to be recorded in the United States this year.
NHL, which is one of the most common cancers in the United States, accounts for about 4% of all types of cancers, according to the American Cancer Society.
Continued approval for the treatment may depend on data from a confirmatory trial, Roche said.
The FDA's accelerated approval program allows conditional approval of a medicine that fills an unmet medical need for a serious condition. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Anil D'Silva and James Emmanuel)